A customer from (b)(6) reported to biomérieux that they were informed of a diagnostic error or an impact on patients' health related to the identified anomalies for fsca 3666, in association with the vitek® 2 gp test kit (lot 240303403).The customer stated they reported an identification of staphylcoccus carnosus sp, and the vitek ms gave no identification.The customer stated there was no consequence or impact to the patient's health, as it concerned a multi-resistant strain.The customer informed biomérieux that the vitek lab report was not available and that the identification could not be confirmed on vitek ms.A biomérieux internal investigation will be initiated.
|
A customer from (b)(6) had reported to biomérieux that they were informed of a diagnostic error or an impact on patients' health related to the identified anomalies for fsca 3666, in association with the vitek® 2 gp id test kit (lot 240303403).The customer stated they reported an identification of staphylcoccus carnosus sp obtained by the vitek 2 gp id card.Vitek ms gave no identification.The customer did not have the lab report available anymore to submit for further evaluation.An internal biomérieux investigation had been performed regarding discrepancies associated with the impacted gp id lot.The investigation was originally opened to investigate atypical o129r negative reactions with the quality control strain enterococcus casseliflavus atcc® 700327¿ in association with vitek® 2 gp id cards.The investigation determined that an atypical negative o129r reaction was possible for cards manufactured with certain lots of raw material.Testing with these lots could result in a positive dsor reaction that occurs early in the incubation of the card, leading to an earlier hour-of-call and the atypical negative reaction for o129r.An atypical negative o129r reaction may result in an organism misidentification at the species level.Fsca-3595, subsequently superseded by fsca-3666, was issued to inform customers of the gp id lots impacted by the identified qc performance issue.In addition, the field corrective action provided guidance to insure a misidentification causes no adverse impact to a patient.Internal measures have been taken in vitek® 2 reagent manufacturing and quality control to prevent recurrence of this type of issue.
|